Milestone Pharmaceuticals closes USD17m Series B Financing
Milestone Pharmaceuticals Inc., a clinical stage cardiovascular company in Phase 2, has closed a USD17 million Series B financing. The round was led by Domain Associates and included participation from all of Milestone's existing investors including Fonds de solidarité FTQ (FSTQ), Pappas Ventures, BDC Capital, GO Capital, and iNovia Capital.




